6 news items
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
KOD
15 May 24
been progressing the manufacturing of KSI-501 and KSI-101 in preparation for their anticipated clinical studies. Clinical material for both KSI-501 (50
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
KOD
13 May 24
and uncertainties that could cause actual results to differ materially and adversely from those in or implied by such forward-looking statements. These risks
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
KOD
2 May 24
that could cause actual results to differ materially and adversely from those in or implied by such forward-looking statements. These risks
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
ABTS
AKAN
ALLG
28 Mar 24
it identified four material weaknesses amid its internal control over financial reporting.
GCT Semiconductor Holding Inc
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
KOD
28 Mar 24
be sufficient to bridge our clinical scale material to our commercial scale, go-to-market material. At the same time, because we have three successful Phase 3
syt0c z8i
KOD
26 Mar 24
actual results to differ materially and adversely from those in or implied by such forward-looking statements. These risks and uncertainties include
- Prev
- 1
- Next